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Malade, Université Paris Descartes, Paris; ‡General Practitioner, Tours; and §Nestlé Waters M.T., Issy-les-Moulineaux, FranceBACKGROUND & AIMS: Little is known about the effects of natural mineral water on constipation in adults. We assessed
the effect of a magnesium sulfate–rich natural mineral water (Hépar; Nestlé Waters, Issy-les-
Moulineaux, France) on gastrointestinal transit in constipated women.METHODS: We performed a randomized, double-blind, placebo-controlled trial to evaluate the efﬁcacy and
safety of Hépar in outpatients with functional constipation (based on the Rome III criteria). The
study included 244 female patients, age 18 to 60 years, identiﬁed by 62 general practitioners
throughout France. After a washout period, subjects drank 1.5 L natural low-mineral water
daily (control, n [ 77), 0.5 L Hépar and 1 L natural low-mineral water daily (Hépar 0.5 group,
n[ 85), or 1 L Hépar and 0.5 L natural low-mineral water daily (Hépar 1 group, n[ 82) for 4
weeks. We collected information on the number and types of stools, abdominal pain, rescue
medications, adverse events, and volume of water consumed.RESULTS: We observed no signiﬁcant effect at week 1. At week 2, constipation was reduced in 21.1% of
patients in the control group, in 30.9% in the Hépar 0.5 group (P [ .099 vs controls), and in
37.5% in the Hépar 1 group (P [ .013 vs controls). The Hépar 1 group also had a decreased
number of hard or lumpy stools (Bristol scale, P[ .030 vs baseline) and a substantial decrease
in the use of rescue medication (P [ .034 vs controls). Patient responses correlated with
magnesium sulfate concentrations. Safety was very good; there were no serious adverse events
among patients who drank Hépar.CONCLUSIONS: In a controlled trial, daily consumption of 1 L Hépar reduced constipation and hard or lumpy
stools in a greater percentage of women with functional constipation than natural low-mineral
water, as early as the second week of treatment.Keywords: Bowel Movement; Clinical Trial; Mineral Water; Treatment.Abbreviations used in this paper: AE, adverse event; FAS, full analysis set;
IBS, irritable bowel syndrome; PAC QoL, patient assessment of con-
stipation quality of life; VAS, visual analogue scale.
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Open access under CC BY-NC-ND license.Chronic idiopathic constipation is a functionalgastrointestinal disorder deﬁned as persistently
difﬁcult, infrequent, or seemingly incomplete defecation
that does not meet the criteria for irritable bowel syn-
drome (IBS). The prevalence of constipation has been
estimated to be 14% and is higher in females.1 It is
associated with a high impact on quality of life and health
care costs.2
First-line recommendations to treat chronic idio-
pathic constipation are lifestyle changes.2–4 Recommen-
dations state that education and nutritional–hygienic
measures including sufﬁcient ﬁber and water intake
should be promoted.5,6 A recent survey supported the
treatment of constipation with increased liquid intake,
rather than with physical exercise or dietary ﬁbers.7
Drugs such as bulking agents, osmotic and stimulatory
laxatives, stool softeners, lubricants, and newer receptor-
based treatments are marketed as second-line treatmentsof constipation. Magnesium and sulfate also have been
shown to increase the frequency and weight of stools,
but these data relied on few studies.8–16
Hépar (Nestlé Waters, Issy-les-Moulineaux, France) is
a magnesium-sulfate–rich natural mineral water widely
marketed in France since 1930. This spring was discov-
ered by Louis Bouloumié in 1873 and was named the
Salted Spring in 1875.17 That year, the French Academy
of Medicine reported that the “salted spring” was “known
[.] as a purgative spring.” The Salted Spring was
declared a “public interest” in 1903 and was renamed
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therapy for the treatment of digestive symptoms.
A clinical trial performed in infants with primary
constipation showed that Hépar signiﬁcantly improves
stool consistency.19 The present study aimed to assess
the efﬁcacy of Hépar in women with chronic idiopathic
constipation deﬁned according to the Rome III criteria.
Two different dosages (0.5 and 1 L/d) and 4 different
periods of evaluation (1, 2, 3, and 4 wk) were tested.Patients and Methods
Study Design
This was a comparative, randomized, double-blind,
placebo-controlled study to evaluate the efﬁcacy and
safety of Hépar (0.5 and 1 L/d) in constipated outpatients.Subjects
Healthy female patients meeting all of the following
inclusion criteria were included in the study: (1) ages 18
to 60 years, (2) a diagnosis of constipation according to
the Rome III criteria20 since at least the past 3 months,
(3) no laxative drug use for 3 days before inclusion, (4)
regularly eats vegetables and fruits, (5) participates in
physical activity such as reasonable walking periods or
exercise 2 or 3 times a week, and (6) drinks 1.5 to 2 L of
water/day. Patients who presented with any of the
following criteria were excluded from the study: (1)
known dislike of Hépar, (2) concomitant treatment that
was likely to interfere with evaluation of the study pa-
rameters, or (3) planned or suspected modiﬁcation of
dietary or physical activity habits within the next 2
months. The study was conducted by 62 city-based
general practitioners located throughout France.Interventions
The washout period comprised the 8 to 9 days before
study inclusion. The patient was instructed to stop any
treatment that was liable to interfere with transit (except
macrogol 4000 [Forlax; Ipsen Pharma, Paris, France]) and
to drink 1.5 L/d of low-mineral spring water (Aquarel;
Nestlé Waters). At the inclusion visit, patients were ran-
domized to the control, Hépar 0.5, or Hépar 1 groups ac-
cording to the chronologic order of arrival and to a
predetermined randomization list in balanced blocks of 3
by center (SAS software version 9.2; SAS Institute, Inc,
Cary, NC). The data manager prepared the list in advance
under the sponsor’s supervision. Two sets of sealed en-
velopes kept by the investigator and the sponsor in a
secure and locked place were generated to contain the
patient’s randomization number and allocated group. The
investigator could break the blinding in case of a serious
adverse event (AE). Three follow-up visits wereperformed at the end of the ﬁrst (week 1), second (week
2), and fourth week of treatment (week 4).
Patients had to drink 1.5 L water per day from day 1
to week 4. Depending on their allocation group, subjects
were instructed to drink 1.5 L of low-mineral water
(control group), 0.5 L Hépar plus 1 L low-mineral water
(Hépar 0.5 group), or 1 L Hépar plus 0.5 L low-mineral
water (Hépar 1 group).
The Hépar total mineralization content is 2513 mg/L
(549 mg/L calcium, 119 mg/L magnesium, 1530 mg/L
sulfate, 14.2 mg/L sodium, 4.1 mg/L potassium, 383.7
mg/L bicarbonate, and 4.3 mg/L nitrate). Its pH is 7.2 at
23C. Hépar currently is marketed in France at a mean
observed cost of 0.74 USD/L (Information Resources, Inc,
Chambourcy, France, in retail, year-to-date October
2013). The placebo was a natural low-mineral water
(Vittel Bonne Source; Nestlé Waters, Issy-les-Moulineaux,
France), which has a total mineralization content of 400
mg/L (94 mg/L calcium, 20 mg/L magnesium, 120 mg/L
sulfate, 7.7 mg/L sodium, 5 mg/L potassium, 248 mg/L
bicarbonate, and <0.5 mg/L nitrate). Hépar and the
placebo were in identical 0.5 L bottles. Both the patient
and the physician were blind to the treatment.
If abdominal pain became higher than 70 on a 100-
mm visual analogue scale (VAS), macrogol 4000 was
authorized until return to the basal abdominal pain level.Measurements
A self-evaluation diary was given to the patients to
collect the following information: (1) the number and
type of stools (Bristol scale),21 (2) abdominal pain, (3)
treatment interruptions, (4) use of rescue medication,
(5) AEs, and (6) the volume of study water intake.
At inclusion, the physician recorded previous medical
history and history of the constipation episode (Rome III
criteria, onset of symptoms, dietary habits, physical ac-
tivities, and previous and current treatments). At each
visit, the physician recorded the following: (1) mean
abdominal pain rating during the past 24 hours (on a
100-mm VAS), (2) AEs, (3) compliance to treatment
(count of unused bottles), and (4) use of rescue medi-
cation over the past week. The patient ﬁlled in the con-
stipation quality of life (PAC QoL) questionnaire.22
Outcomes
The primary end point was response to a 1-week 0.5
or 1 L/d Hépar treatment. It was evaluated based on 2
separate components of the Rome III criteria: (1) 4 stools
or more per week, or an increase of 2 stools or more as
compared with baseline, and (2) less than 25% of lumpy
or hard stools. Both of these criteria were required to
consider a patient as responsive to treatment.
The secondary end points were as follows: (1)
response to treatment at weeks 2 and 4 as described for
the primary criterion, (2) stools consistency (Bristol
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criteria for functional constipation, (4) abdominal pain,
(5) the Clinician’s and the Patient’s Global Impression of
Change, (6) the PAC QoL scale (individual dimensions
and total score),22 and (7) use of rescue medication.
Sample Size Calculation
The number of subjects required was calculated
based on a unilateral Cochran–Armitage test23 with an a
risk level of .05 and a statistical power of 90%. Hy-
potheses were 10% of responders in the control group,
20% in the Hépar 0.5 group, and 30% in the Hépar 1
group. The number of patients needed was 72 per group
(total of 216 patients completing the study). Anticipating
a 5% rate of inappropriate selection and a 15% drop-out
rate, 270 patients had to be screened.
Statistical Analyses
The primary end point was analyzed according to the
principles for a full analysis set (FAS) recommended by
the International Conference on Harmonisation topic
E9.24 The FAS included all the randomized patients who
had used the study product at least once and were
evaluated at baseline for the number and consistency of
stools, and the primary end point at week 1 (or before in
case of early withdrawal from the study).
Quantitative variables are described using mean and
standard deviation (SD), and qualitative variables are
described using number and percentage. The level of
signiﬁcance was set at an a value of .05.
The proportions of responders were compared
using the 1-sided Cochran–Armitage trend test. Stool con-
sistencies were compared using the Wilcoxon signed-ranktest. Comparison between treatment groups of the number
of stools, abdominal pain, and PAC QoL scores was per-
formed using repeated-measures analysis of covariance.
Statistical analyses were performed using SAS soft-
ware (version 9.2; SAS Institute).
Ethics
All patients provided signed informed consent. The
protocol was approved by the French North-West 6
ethics committee and the French Regulatory Agency
(Agence Nationale de Sécurité du Médicament et des
Produits de Santé). It was conducted in accordance with
the principles of the Helsinki Declaration and its subse-
quent amendments, and in accordance with Good Clinical
Practice (Committee for Proprietary Medicinal Products/
International Conference on Harmonisation/135/95).
Because the tested product was not a health care
product, no registration with a clinical trial registry was
required. Authors had access to the study data and
reviewed and approved the ﬁnal manuscript.
Results
Population
A ﬂow chart of the patients included in the study is
presented in Figure 1. A total of 244 female patients
were randomized to the control (n ¼ 77), Hépar 0.5
(n ¼ 85), or the Hépar 1 (n ¼ 82) groups. Two patients in
the Hépar 0.5 group were excluded from the FAS popu-
lation (n ¼ 242) because of no use (n ¼ 1) or use of the
study treatment for fewer than 7 days (n ¼ 1). The pa-
tients mean (SD) age was 42.4  11 years, the mean
height 163.6  6.7 cm, and the mean weight wasFigure 1. Flow chart of the
patients.
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score ranged from 28.2  6.9 (Hépar 1 group) to
28.4  6.6 (control group). It corresponded to mild
constipation in 16.8% of the patients, to moderate con-
stipation in 64.8%, and to severe constipation in 18.4%.
No statistically signiﬁcant difference was observed be-
tween groups at inclusion.Treatment Efﬁcacy
Compliance to the treatment was very good: 103.1%
 12.5% of the theoretical consumption in the control
group, 100.0%  15.3% in the Hépar 0.5 group, and
101.6%  13.6% in the Hépar 1 group.
The proportion of responders during week 1 (ie, the
primary end point) was 24.7% in the control group,
32.5% in the Hépar 0.5 group, and 34.1% in the Hépar 1
group (Figure 2A). The difference between groups was
not statistically signiﬁcant for the primary end point,
although a trend was observed (P ¼ .099).
Statistical signiﬁcance was reached during the second
week of treatment (P ¼ .013), during which the Hépar 1
group showed a higher proportion of responders than
the control group (þ16.4%; 95% conﬁdence interval,
2.4%–30.4%). The Hépar 1 group showed a signiﬁcantly
higher proportion of responders at week 4 (P ¼ .028),
with 14.7% more responders in the Hépar 1 group than
in the control group (95% conﬁdence interval, .1%–
29.3%). The Hépar 0.5 group did not show a statistically
signiﬁcant difference with the control group, at any visit.
Stool consistency was improved signiﬁcantly at week 2
in the Hépar 1 group, which showed decreased proportions
of hard or lumpy stools (P ¼ .030) and an increased
number of normal stools (P ¼ .014) (Supplementary
Table 1 and Figure 3). A trend was observed throughout
the study toward a higher number of normal stools in the
Hépar 1 group (P ¼ .090 at week 1, P ¼ .080 at week 3,
and P¼ .091 at week 4). The Hépar 0.5 group did not show
improved stool consistency. No signiﬁcant variation was
observed between groups or weeks of treatment regarding
the number of stools (Supplementary Table 2).Table 1. Patient Characteristics at Inclusion: Intent-to-Treat
Population
Control
(n ¼ 77)
Hépar 0.5
(n ¼ 85)
Hépar 1
(n ¼ 82)
Age, y, mean  SD 40.8  12.4 44.4  10.5 41.7  10.3
Height, cm, mean  SD 163.9  6.3 164.0  7.1 163.7  6.7
Weight, kg, mean  SD 63.3  11.0 64.1  12.3 63.1  11.6
Rome III score,
mean  SD
28.4  6.6 28.3  6.7 28.2  6.9
Classes, n (%)
Mild, 22 12 (15.6) 12 (14.1) 17 (20.7)
Moderate, 23–34 51 (66.2) 58 (68.2) 49 (59.8)
Severe, 35 14 (18.2) 15 (17.6) 16 (19.5)Abdominal Pain
Abdominal pain did not vary signiﬁcantly between
groups or weeks (Supplementary Table 3). However,
post hoc analyses according to abdominal pain showed
very interesting results (Figure 4). In the control (n ¼ 8)
and Hépar 0.5 (n ¼ 7) groups, patients with baseline
abdominal pain greater than 72 on the 100-mm VAS
showed slight decreases in the Rome III score from
baseline to week 1 (-15% and -12%, respectively) and
week 4 (-13% and -15%, respectively). The decrease in
the Rome III score in patients with baseline abdominal
pain greater than 72 on the VAS was substantial with 1 L
Hépar (n ¼ 9) from baseline to week 1 (-41%) and week
4 (-48%), but the too low number of patients resulted in
an absence of statistically signiﬁcant difference.
Quality of Life and Rescue Medication
Evolution of the PAC QoL score did not differ between
groups or weeks of treatment (Supplementary Table 3).
Nonetheless, the use of rescue medication was decreased
signiﬁcantly in the Hépar 1 group as compared with the
control group (Figure 5). At week 2, although the use of
rescue medication was observed in 12 (15.8%) patients in
the control group, it was observed in 9 (11.4%) patients in
the Hépar 0.5 group (P ¼ .424), and in only 4 (5.3%) pa-
tients in theHépar1group (P¼ .034).Atweek4, therewere
14 (19.7%) patients using rescuemedication in the control
group, 7 (9.2%) patients in the Hépar 0.5 group (P¼ .069),
and 2 (2.8%) patients in the Hépar 1 group (P ¼ .001).
Mg2þ and SO4
2- Concentration and Proportion
of Responders
To evaluate if the laxative effect of Hépar could be
related to its content in magnesium and sulfate, addi-
tional analyses were performed on the relationship be-
tween response to the treatment and total osmolarity per
week in magnesium and sulfate (Figure 2B). Results
showed that the percentage of responders increased in
relation to the concentration in sulfate and magnesium.
Safety
A total of 39 patients reported 74 AEs during the study:
13 patients in the control group (25 AEs), 15 in the Hépar
0.5 group (28 AEs), and 11 in the Hépar 1 group (21 AEs).
Most AEs (24, 25, and 20 AEs, respectively) were
treatment-emergent (ie, occurred or worsened after expo-
sure to the treatment). A relationship to the study treat-
ment was likely for 2 patients in the control group (2 AEs),
1 patient in the Hépar 0.5 group (1 AE), and 2 patients in
the Hépar 1 group (4 AEs). Intensity was rated as mild for
most AEs (18, 22, and 19, respectively) and moderate for 6
AEs in the control group, 6 in the Hépar 0.5 group, and 2 in
the Hépar 1 group. One serious AE (ie, pregnancy) was
Figure 2. (A) Proportion of
responders in each group
and at each evaluation
period (FAS population) (B)
according to the Mg2þ and
SO4
2- osmolarity of the
treatment at each evaluation
period (FAS population).
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the Hépar 0.5 or Hépar 1 groups. Most frequent AEs con-
cerned the gastrointestinal tract. The most frequent AE was
diarrhea, which occurred in 5 patients in the control group,
in 7 patients in the Hépar 0.5 group, and in 7 patients in the
Hépar 1 group.Discussion
The present study showed that as early as the second
week of treatment, the consumption of 1 L Héparreduced functional constipation. This effect was main-
tained over the 4 weeks of study and seemed higher in
patients with higher levels of abdominal pain.
Hépar is a natural mineral water rich in magnesium,
sulfate, and calcium, and has a long history of a pur-
gative effect. Because we failed to ﬁnd data concerning
the effect of a natural mineral water on constipation,
we decided to study 2 different dosages (0.5 and 1 L/d)
and to perform an evaluation over a period of 4 weeks.
The choice for the time measurement of the primary
end point was a matter of discussion. To better esti-
mate the dynamics of the effect of Hépar intake,
Figure 3. Change in stool consistency from baseline to week
2 (Bristol scale, FAS population). Types I and II, hard or lumpy
stool; types III through V, normal stool; types VI and VII, loose
to liquid stool. *P < .05.
Figure 5. Use of rescue medication (ie, macrogol 4000) (FAS
population). *P < .05; ***P < .001.
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It also was decided that the primary end point would
be based on 2 of the Rome III criteria: (1) 4 or more
stools per week, or improvement by 2 or more stools
per week, and (2) less than 25% of lumpy or hard
stools. These criteria were chosen because they are
both good indicators of intestinal motility.20,21 How-
ever, because this was a population-based study per-
formed by general practitioners, no accurate diagnosis
could be practically performed (using radiography or
anorectal measurements) to precisely classify patients
into functional constipation, slow-transit constipation,
or outlet-dysfunction constipation. It also is probable
that a small part of the patients had constipation-
predominant IBS, but the low level of abdominal pain
at inclusion suggests that few constipation-
predominant IBS patients were included. Nonetheless,
because these conditions usually show a poorer
response to treatments than functional constipation,
having included such patients might have decreased
the power of the study.Figure 4. Evolution of the
Rome III score according
to the baseline level of
abdominal pain (VAS
scale, 0–100 mm) (FAS
population).The primary end point at week 1 was negative, but a
signiﬁcant response to the treatment was observed at
week 2 and was associated with decreased use of rescue
medication. No post hoc analysis was performed to
determine exactly when this occurred, but these results
show that drinking 1 L Hépar per day for 8 to 14 days
signiﬁcantly improves symptoms of functional con-
stipation. Although not statistically signiﬁcant, the effect
seemed higher in patients with higher abdominal pain
(VAS >72). In addition, the use of Hépar was associated
with a very good safety proﬁle because only 1 serious AE
was reported in the control group. Overall, these data
indicate that consumption of 1 L Hépar per day for 1 to 2
weeks might be a ﬁrst-line treatment in patients with
functional constipation. These data are supported by
those of a previous study conducted in constipated
infants.19
From a mechanistic point of view, the laxative effect
of Hépar on constipation most likely is related to its
high magnesium and sulfate content. In France, Hépar
is the natural mineral still water with the highest
1286 Dupont et al Clinical Gastroenterology and Hepatology Vol. 12, No. 8content in magnesium (119 mg/L) and sulfate (1530
mg/L). A recent study showed that although low
magnesium intake was associated with constipation,
high doses of oral magnesium have a laxative effect.14
Sulfate increases the weight and consistency of stools,
and intestinal motility, at doses of more than 1000 to
1500 mg/d.8,10,16 High doses of magnesium sulfate
(>2000 mg/d) were as efﬁcient as polyethylene glycol
to improve the frequency and consistency of stools.9,15
This effect of magnesium and sulfate might be related
to the fact that they are absorbed moderately from the
intestinal lumen, exert an osmotic effect that retains
water, and, thereby, increases the ﬂuidity of the
intraluminal contents. However, additional mecha-
nisms have been proposed such as a possible increase
in the release of cholecystokinin and activation of the
nitric oxide synthase.12 In vivo studies have suggested
that it is related to an increase in both osmolarity and
expression of the aquaporin-3 transport protein.11
These data are supported by the analyses we per-
formed, which showed a dose-response relationship
between osmolarity in magnesium and sulfate and
response to the treatment.Conclusions
The intake of 1 L Hépar per day for 1 to 2 weeks
resulted in a signiﬁcant improvement of the gastroin-
testinal transit of patients with chronic idiopathic con-
stipation deﬁned according to the Rome III criteria. This
laxative effect lasted until the fourth week of treatment
and was associated with a very good safety proﬁle. The
primary criterion was not statistically signiﬁcant, but this
study showed that a natural mineral water can be efﬁ-
cient in the treatment of chronic idiopathic constipation.
The consumption of a magnesium sulfate–rich natural
mineral water seems to be a ﬁrst-line solution in func-
tional constipation before initiation of a drug treatment.
Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
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